Suchen
Amarin Corporation PLC
AMRNZur Watchlist hinzufügen
14.560USD
-0.220-1.49%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
301.53MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Amarin Corporation PLC Unternehmen
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corporation PLC Informationen
BörsenkürzelAMRN
Name des UnternehmensAmarin Corporation PLC
IPO-datumApr 01, 1993
CEOBerg (Aaron D)
Anzahl der mitarbeiter275
WertpapierartDepository Receipt
GeschäftsjahresendeApr 01
AddresseWeWork One Central Plaza Dame Street
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
PostleitzahlD02 K7K5
Telefon35316699020
Websitehttps://amarincorp.com/
BörsenkürzelAMRN
IPO-datumApr 01, 1993
CEOBerg (Aaron D)
Führungskräfte von Amarin Corporation PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
11.71K
+32.10%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
836.00
+52.03%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
836.00
+52.03%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
801.00
+49.94%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
11.71K
+32.10%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
836.00
+52.03%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
836.00
+52.03%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
801.00
+49.94%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Sarissa Capital Management, L.P.
8.08%
Acadian Asset Management LLC
2.80%
Kynam Capital Management LP
1.88%
Morgan Stanley & Co. LLC
1.37%
WaterFront Wealth, Inc.
0.98%
Andere
84.89%
Aktionäre
Aktionäre
Anteil
Sarissa Capital Management, L.P.
8.08%
Acadian Asset Management LLC
2.80%
Kynam Capital Management LP
1.88%
Morgan Stanley & Co. LLC
1.37%
WaterFront Wealth, Inc.
0.98%
Andere
84.89%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
13.92%
Investment Advisor/Hedge Fund
3.48%
Investment Advisor
2.67%
Research Firm
2.18%
Individual Investor
1.07%
Pension Fund
0.31%
Family Office
0.27%
Venture Capital
0.08%
Andere
76.02%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
280
4.71M
22.72%
-402.42K
2025Q4
291
4.18M
22.49%
+4.06K
2025Q3
314
4.20M
24.13%
+467.66K
2025Q2
330
3.80M
23.58%
+94.36K
2025Q1
338
3.76M
23.88%
-1.19M
2024Q4
355
3.75M
23.57%
+236.09K
2024Q3
360
3.51M
29.65%
-554.68K
2024Q2
386
4.06M
34.43%
-548.92K
2024Q1
399
4.62M
36.64%
-2.90M
2023Q4
416
4.89M
38.80%
+197.93K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sarissa Capital Management, L.P.
1.67M
8.04%
+430.87K
+34.68%
Dec 31, 2025
Acadian Asset Management LLC
580.44K
2.79%
+123.86K
+27.13%
Dec 31, 2025
Kynam Capital Management LP
389.27K
1.87%
-186.84K
-32.43%
Dec 31, 2025
Morgan Stanley & Co. LLC
283.19K
1.36%
+31.77K
+12.64%
Dec 31, 2025
WaterFront Wealth, Inc.
142.54K
0.69%
+64.58K
+82.84%
Dec 31, 2025
Eversept Partners, LP
172.19K
0.83%
+4.91K
+2.94%
Dec 31, 2025
Citadel Advisors LLC
168.00K
0.81%
+45.71K
+37.38%
Dec 31, 2025
Millennium Management LLC
166.24K
0.8%
+33.84K
+25.56%
Dec 31, 2025
Two Sigma Investments, LP
148.16K
0.71%
+71.30K
+92.75%
Dec 31, 2025
Berg (Aaron D.)
82.59K
0.4%
+1.88K
+2.33%
Jan 31, 2026
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
SPDR S&P International Small Cap ETF
Anteil0.02%
Global X Aging Population ETF
Anteil0%
ActivePassive International Equity ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1
